↓ Skip to main content

Methotrexate-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses

Overview of attention for article published in Cancer Chemotherapy and Pharmacology, May 2016
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 X user

Citations

dimensions_citation
58 Dimensions

Readers on

mendeley
123 Mendeley
Title
Methotrexate-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses
Published in
Cancer Chemotherapy and Pharmacology, May 2016
DOI 10.1007/s00280-016-3043-5
Pubmed ID
Authors

Jared M. Campbell, Emma Bateman, Matthew D. Stephenson, Joanne M. Bowen, Dorothy M. Keefe, Micah D. J. Peters

Abstract

Methotrexate chemotherapy is associated with various toxicities which can result in the interruption or discontinuation of treatment and a subsequently raised risk of relapse. This umbrella systematic review was conducted to synthesize the results of all existing systematic reviews that investigate the pharmacogenetics of methotrexate-induced toxicity, with the aim of developing a comprehensive reference for personalized medicine. Databases searched were PubMed, Embase, JBI Database of Systematic Reviews and Implementation Reports, DARE, and ProQuest. Papers were critically appraised by two reviewers, and data were extracted using a standardized tool. Three systematic reviews on methotrexate-induced toxicity were included in the review. Meta-analyses were reported across Asian, Caucasian, pediatric and adult patients for the MTHFR C677T and A1298C polymorphisms. Toxicity outcomes included different forms of hematologic, ectodermal and hepatic toxicities. Results varied considerably depending on the patient groups and subgroups investigated in the different systematic reviews, as well as the genetic models utilized. However, significant associations were found between the MTHFR C677T allele and; hepatic toxicity, myelosuppression, oral mucositis, gastrointestinal toxicity, and skin toxicity. Additionally, limited evidence suggests that the MTHFR A1298C polymorphism may be associated with decreased risk of skin toxicity and leukopenia. This umbrella systematic review has synthesized the best available evidence on the pharmacogenetics of methotrexate toxicity. The next step in making personalized medicine for methotrexate therapy a clinical reality is research on the effectiveness and cost-effectiveness of MTHFR genotype testing to enable the close monitoring of at-risk patients for the timely initiation of rescue therapies.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 123 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 123 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 15 12%
Student > Master 14 11%
Student > Bachelor 13 11%
Student > Postgraduate 12 10%
Student > Doctoral Student 11 9%
Other 21 17%
Unknown 37 30%
Readers by discipline Count As %
Medicine and Dentistry 41 33%
Pharmacology, Toxicology and Pharmaceutical Science 13 11%
Biochemistry, Genetics and Molecular Biology 7 6%
Agricultural and Biological Sciences 4 3%
Social Sciences 3 2%
Other 9 7%
Unknown 46 37%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 May 2016.
All research outputs
#19,221,261
of 23,815,455 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#2,044
of 2,501 outputs
Outputs of similar age
#221,321
of 300,493 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#15
of 34 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,501 research outputs from this source. They receive a mean Attention Score of 4.1. This one is in the 11th percentile – i.e., 11% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 300,493 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 34 others from the same source and published within six weeks on either side of this one. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.